Orchard To Work On Reversing English Funding Refusal For Libmeldy Gene Therapy
Reimbursement Discussions Are Also Ongoing In Other Major European Markets
Executive Summary
Health technology assessment body NICE has welcomed further discussion between Orchard Therapeutics and the National Health Service to resolve its concerns over the company’s one-time gene therapy for the neurodegenerative disorder, metachromatic leukodystrophy, in children.
You may also be interested in...
Libmeldy: ‘Significant Discount’ For World’s Most Expensive Drug Secures English Funding
Orchard Therapeutics has agreed to lower the price of its £2.8m gene therapy for children with metachromatic leukodystrophy following negotiations with the National Health Service. Meanwhile, reimbursement efforts in the rest of Europe are also gaining speed and a US filing is planned.
Libmeldy Gene Therapy Brings Considerable Extra Benefit, Says German Body
With talks to form a new coalition progressing in Germany, the new government, which could take office in early December, is expected to introduce measures to curb pharmaceutical spending. Orphan drugs could be among products targeted.
‘Substantial’ Discount Helps Zolgensma Win Access In UK
The English and Scottish health technology appraisal bodies NICE and the Scottish Medicines Consortium have given the green light to Novartis/Avexis’ costly gene therapy, Zolgensma.